Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Ironwood Pharmaceuticals is a drug manufacturers-specialty & generic business based in the US. Ironwood Pharmaceuticals shares (IRWD) are listed on the NASDAQ and all prices are listed in US Dollars. Ironwood Pharmaceuticals employs 219 staff and has a trailing 12-month revenue of around $420.5 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $11.31 |
|---|---|
| 52-week range | $9.73 - $12.95 |
| 50-day moving average | $11.84 |
| 200-day moving average | $11.48 |
| Wall St. target price | $13.00 |
| PE ratio | 12.3226 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.93 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.31 from 2023-01-26
| 1 week (2023-01-20) | -0.88% |
|---|---|
| 1 month (2022-12-27) | -7.30% |
| 3 months (2022-10-27) | 3.67% |
| 6 months (2022-07-27) | -8.50% |
| 1 year (2022-01-26) | 4.24% |
|---|---|
| 2 years (2021-01-27) | 8.85% |
| 3 years (2020-01-27) | 12.18 |
| 5 years (2018-01-26) | 16.2702 |
Valuing Ironwood Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ironwood Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ironwood Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Ironwood Pharmaceuticals shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Ironwood Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $240.3 million.
The EBITDA is a measure of a Ironwood Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $420.5 million |
|---|---|
| Operating margin TTM | 56.8% |
| Gross profit TTM | $343.3 million |
| Return on assets TTM | 14.09% |
| Return on equity TTM | 28.62% |
| Profit margin | 39.85% |
| Book value | $3.86 |
| Market capitalisation | $1.8 billion |
TTM: trailing 12 months
We're not expecting Ironwood Pharmaceuticals to pay a dividend over the next 12 months.
Ironwood Pharmaceuticals's shares were split on a 1194:1000 basis on 1 April 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1194 shares. This wouldn't directly have changed the overall worth of your Ironwood Pharmaceuticals shares – just the quantity. However, indirectly, the new 16.2% lower share price could have impacted the market appetite for Ironwood Pharmaceuticals shares which in turn could have impacted Ironwood Pharmaceuticals's share price.
Over the last 12 months, Ironwood Pharmaceuticals's shares have ranged in value from as little as $9.73 up to $12.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ironwood Pharmaceuticals's is 0.9487. This would suggest that Ironwood Pharmaceuticals's shares are less volatile than average (for this exchange).
Ironwood Pharmaceuticals, Inc. , a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc. , AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
